Activity of Gemcitabine in Platinum-resistant Ovarian Germ Cell Cancer

By Maas K.   Daikeler T.   Kanz L.   Bokemeyer C.  

European Journal of Cancer, Vol. 32, Iss. 8, 1996-07 ,pp. : 1437-1438

Elsevier

Access to resources Recommend Favorite

Pharmacology of the paclitaxel–cisplatin, gemcitabine–cisplatin, and paclitaxel–gemcitabine combinations in patients with advanced non-small cell lung cancer

By Kroep J.   Smit E.   Giaccone G.   Born K.   Beijnen J.   Groeningen C.   Vijgh W.   Postmus P.   Pinedo H.   Peters G.  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 4, 2006-10 ,pp. : 509-516

Springer Publishing Company

Access to resources Recommend Favorite

Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer

By Markman M.   Webster K.   Zanotti K.   Kulp B.   Peterson G.   Belinson J.  

Gynecologic Oncology, Vol. 90, Iss. 3, 2003-09 ,pp. : 593-596

Elsevier

Access to resources Recommend Favorite

Cost-Utility Analysis of Paclitaxel in Combination with Cisplatin for Patients with Advanced Ovarian Cancer

By Ortega A.   Dranitsaris G.   Sturgeon J.   Sutherland H.   Oza A.  

Gynecologic Oncology, Vol. 66, Iss. 3, 1997-09 ,pp. : 454-463

Elsevier

Access to resources Recommend Favorite

Long-term Prognosis Following Macroscopic Complete Response at Second-look Laparotomy in Advanced Ovarian Cancer Patients Treated with Platinum-based Chemotherapy

By Chiara S.   Lionetto R.   Campora E.   Oliva C.   Merlini L.   Bruzzi P.   Rosso R.   Conte P.F.  

European Journal of Cancer, Vol. 31, Iss. 3, 1995-01 ,pp. : 296-301

Elsevier

Access to resources Recommend Favorite